- Investing.com
Strategic Crossroads | Zimmer Biomet navigates challenging market conditions while pursuing strategic acquisitions in robotic orthopedic surgery to secure long-term competitive advantages. |
Financial Headwinds | Analyst price targets range from $101 to $125, reflecting mixed sentiment amid increased operational expenditures and tariff impacts expected to pressure profit margins. |
Product Pipeline Promise | Delve into how two major knee product launches in 2025 could revitalize Zimmer's core business, potentially offsetting recent underperformance in the U.S. Knees segment. |
Competitive Evolution | Explore Zimmer Biomet's positioning in the evolving orthopedic device market, where the Monogram Technologies acquisition signals commitment to leadership in robotic surgery technology. |
Metrics to compare | ZBH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZBHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 23.2x | 28.1x | −0.4x | |
PEG Ratio | −1.60 | −0.26 | 0.00 | |
Price/Book | 1.4x | 1.6x | 2.6x | |
Price / LTM Sales | 2.1x | 1.8x | 3.0x | |
Upside (Analyst Target) | 4.3% | 25.4% | 53.2% | |
Fair Value Upside | Unlock | 27.9% | 9.0% | Unlock |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.